Frontier Investment Mgmt Company Lowered Nvidia (NVDA) Stake; Syndax Pharmaceuticals (SNDX) Shorts Down By 42.29%

June 17, 2018 - By Adrian Erickson

NVIDIA Corporation (NASDAQ:NVDA) Logo

Syndax Pharmaceuticals Inc (NASDAQ:SNDX) had a decrease of 42.29% in short interest. SNDX’s SI was 967,500 shares in June as released by FINRA. Its down 42.29% from 1.68M shares previously. With 352,400 avg volume, 3 days are for Syndax Pharmaceuticals Inc (NASDAQ:SNDX)’s short sellers to cover SNDX’s short positions. The SI to Syndax Pharmaceuticals Inc’s float is 5.77%. The stock increased 3.12% or $0.26 during the last trading session, reaching $8.6. About 349,232 shares traded or 9.48% up from the average. Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) has declined 29.80% since June 17, 2017 and is downtrending. It has underperformed by 42.37% the S&P500. Some Historical SNDX News: ; 17/05/2018 – Oncolytics Biotech® Announces Collaboration with Merck and Northwestern University Combining Keytruda® and REOLYSIN® in a Ph; 17/05/2018 – Syndax Pharmaceuticals Presenting at Conference Jun 3; 30/04/2018 – Merck Has Submitted Keytruda Combination For FDA Approval — MarketWatch; 20/03/2018 – Roche’s Tecentriq with Chemotherapy Phase III IMpower131 Study Met Co-Primary Endpoint; 15/04/2018 – Merck: Safety Profile of Keytruda Consistent With Previous Trials of Patients With Advanced Melanoma; 16/05/2018 – Phase lll lMpower150 Study Showed Genentech’s TECENTRIQ and Avastin Plus Carboplatin and Paclitaxel Helped People With a Specific Type of Metastatic Lung Cancer Live Significantly Longer Compared to Avastin Plus Carboplatin and Paclitaxel; 29/05/2018 – Roche’s Tecentriq meets targets in lung cancer trial; 10/05/2018 – GENENTECH PROVIDES UPDATE ON PHASE lll STUDY OF TECENTRIQ (ATEZOLIZUMAB) AND COTELLIC (COBIMETINIB) IN PEOPLE WITH HEAVILY PRE-TREATED LOCALLY ADVANCED OR METASTATIC COLORECTAL CANCER; 13/03/2018 – FDA PRIORITY REVIEW OF KEYTRUDA IN ADVANCED CERVICAL CANCER; 17/05/2018 – Eisai Announces Data at ASCO 2018 Annual Meeting Showcasing LENVIMA® (lenvatinib) and KEYTRUDA® (pembrolizumab) Combination Therapy Under Strategic Oncology Collaboration with Merck

Frontier Investment Mgmt Company decreased Nvidia Corp (NVDA) stake by 0.91% reported in 2018Q1 SEC filing. Frontier Investment Mgmt Company sold 194 shares as Nvidia Corp (NVDA)’s stock rose 1.09%. The Frontier Investment Mgmt Company holds 21,144 shares with $4.90B value, down from 21,338 last quarter. Nvidia Corp now has $161.01 billion valuation. The stock decreased 0.62% or $1.65 during the last trading session, reaching $265.26. About 9.08M shares traded. NVIDIA Corporation (NASDAQ:NVDA) has risen 80.30% since June 17, 2017 and is uptrending. It has outperformed by 67.73% the S&P500. Some Historical NVDA News: ; 27/03/2018 – NVIDIA CEO SAYS UBER FATALITY SHOULD NOT DISCOURAGE SELF-DRIVING DEVELOPMENT, BUT “BRING AWARENESS TO THE IMPORTANCE OF lT”; 30/04/2018 – Fidelity Select Electronics Adds NXP Semi, Buys More Nvidia; 11/05/2018 – Cramer pushes back on concerns about Nvidia’s cryptocurrency-mining segment; 18/04/2018 – Some of the major market leaders getting back in the saddle again! $AMZN $BA $CAT $GOOGL and $NVDA all surging and nearing their recent highs; 14/05/2018 – Old Mutual Adds eBay, Exits CVS, Cuts Nvidia: 13F; 15/03/2018 – Selling GE, Intel, AMD, Micron, Buying Nvidia — Barrons.com; 27/03/2018 – U.S. opens probe into fatal Tesla crash, fire in California; 02/04/2018 – Analyst slashes profit forecast for Nvidia due to plunging cryptocurrency prices; 27/03/2018 – Techmeme: Source: Nvidia will suspend self-driving tests globally, following Uber’s self-driving incident last week (Reuters); 26/03/2018 – Teradata Joins NVIDIA Partner Program Focused on Accelerating Outcomes from Al, Deep Learning in Key Industries

More important recent Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) news were published by: Seekingalpha.com which released: “Syndax: One Step Backward, Two Forward?” on May 23, 2018, also Seekingalpha.com published article titled: “Syndax Pharmaceuticals: Elucidating The Results Of The Phase 2 ENCORE 601 Trial”, Seekingalpha.com published: “Syndax and Nektar Therapeutics team up in study of doublet therapy for advanced melanoma” on May 30, 2018. More interesting news about Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) was released by: Seekingalpha.com and their article: “Syndax Falls On ASCO Abstract Results, But Was Its Drop Justified At This Time?” with publication date: May 21, 2018.

Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company has market cap of $212.47 million. The companyÂ’s lead product candidate is Entinostat, which is in Phase III clinical trial for the treatment of hormone receptor positive, human epidermal growth factor receptor 2 negative, and breast cancer; and Phase 2b clinical trial. It currently has negative earnings. It also develops SNDX-6352, an immunoglobulin G subclass 4 isotype that binds to the ligand binding domain of CSF-1R, blocking the binding and consequent activation by natural ligands interleukin-34 and colony stimulating factor-1, and disrupting tumor-associated macrophages activity.

Among 45 analysts covering Nvidia Corporation (NASDAQ:NVDA), 27 have Buy rating, 3 Sell and 15 Hold. Therefore 60% are positive. Nvidia Corporation had 205 analyst reports since August 3, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Friday, August 12 by UBS. Wedbush maintained the shares of NVDA in report on Friday, February 12 with “Outperform” rating. The firm has “Buy” rating given on Friday, November 11 by Mizuho. The stock has “Buy” rating by Canaccord Genuity on Monday, July 24. The stock of NVIDIA Corporation (NASDAQ:NVDA) earned “Buy” rating by Loop Capital on Tuesday, December 13. The firm has “Hold” rating by KeyBanc Capital Markets given on Tuesday, June 20. Jefferies maintained NVIDIA Corporation (NASDAQ:NVDA) on Thursday, September 14 with “Buy” rating. The stock has “Buy” rating by Citigroup on Friday, January 12. As per Wednesday, June 28, the company rating was maintained by Mizuho. Stifel Nicolaus maintained the stock with “Hold” rating in Friday, November 10 report.

Frontier Investment Mgmt Company increased Verizon Communications (NYSE:VZ) stake by 1,377 shares to 491,156 valued at $23.49 billion in 2018Q1. It also upped Schwab U.S. Dividend Equity Et (SCHD) stake by 2,455 shares and now owns 29,246 shares. Becton Dickinson & Co (NYSE:BDX) was raised too.

More notable recent NVIDIA Corporation (NASDAQ:NVDA) news were published by: Seekingalpha.com which released: “Nvidia: Growing But Expensive” on June 11, 2018, also Seekingalpha.com with their article: “PVAC +3.7%, FLT +4.5% on index changes; NVDA to S&P 100” published on June 15, 2018, Seekingalpha.com published: “AI At The Edge: Nvidia’s Robotics Opportunity” on June 12, 2018. More interesting news about NVIDIA Corporation (NASDAQ:NVDA) were released by: Nasdaq.com and their article: “NVIDIA Corporation (NVDA) Launches Enhanced AI Platform, Partners With MOST” published on June 04, 2018 as well as Seekingalpha.com‘s news article titled: “Nvidia: 2018 Target Prices” with publication date: June 07, 2018.

Analysts await NVIDIA Corporation (NASDAQ:NVDA) to report earnings on August, 9. They expect $1.64 EPS, up 78.26% or $0.72 from last year’s $0.92 per share. NVDA’s profit will be $995.48M for 40.44 P/E if the $1.64 EPS becomes a reality. After $1.88 actual EPS reported by NVIDIA Corporation for the previous quarter, Wall Street now forecasts -12.77% negative EPS growth.

NVIDIA Corporation (NASDAQ:NVDA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>